EXCLUSIVE: NRx Pharmaceuticals CEO Jonathan Javitt, On Co.'s Trial Data Of Aviptadil, Says 'The improvement in the test group's overall respiratory distress ratio and cytokine levels add biologic credibility to the positive findings from this study'
Zoltan Suranyi - Oct 14, 2021, 12:53PM